Unclaimed Scholar Profile
Are you Helen McIlleron? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarVerified at University of Cape TownASIDASID-1097-8883-6864 orcid.org/0000-0002-0982-6226
Helen McIlleron
University of Cape Town•South Africa
Faculty researcher at University of Cape Town (ZA), specializing in Physical Sciences & Engineering. [Discipline: Physical Sciences & Engineering] [Scholar Type: Policy & Economics Specialist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#Tuberculosis Research and Epidemiology#Antibiotics Pharmacokinetics and Efficacy#HIV/AIDS drug development and treatment#Pharmacogenetics and Drug Metabolism
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 10,083 | 4,840 |
| h-index | 56 | 42 |
| i10-index | 165 | 115 |
Annual Citation Growth
Verified Citations / Year0
2020484
2021+40%678
2022+28%871
2023+33%1.2k
2024-8%1.1k
2025-45%581
2026Scholarship Distribution & Proportions242 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:82% African Regional Citations (8,268) • 18% Global Research Impact (1,815)
242 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (242)
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Published in The Lancet Respiratory Medicine•2017
DOI: 10.1016/s2213-2600(17)30079-6 Verified Peer-Reviewed
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Published in The Journal of Infectious Diseases•2013
DOI: 10.1093/infdis/jit352 Verified Peer-Reviewed
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Published in New England Journal of Medicine•2014
DOI: 10.1056/nejmoa1314210 Verified Peer-Reviewed
Global tuberculosis drug development pipeline: the need and the reality
Published in The Lancet•2010
DOI: 10.1016/s0140-6736(10)60359-9 Verified Peer-Reviewed
Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients
Published in Antimicrobial Agents and Chemotherapy•2006
DOI: 10.1128/aac.50.4.1170-1177.2006 Verified Peer-Reviewed
Showing 1 – 5 of 242 publications
1 / 49